You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Claims for Patent: 9,566,252

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,566,252

Title:	Method for the alleviation of dyspareunia in women
Abstract:	This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.
Inventor(s):	Halonen; Kaija (Rusko, FI), Kangas; Lauri (Lieto, FI), DeGregorio; Michael W. (Granite Bay, CA)
Assignee:	HORMOS MEDICAL LTD. (Turku, FI)
Application Number:	12/837,292
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,566,252
Patent Claims:	1. A method for alleviating dyspareunia during or after menopause, said method comprising administering to a woman in need thereof an effective amount of (deaminohydroxy)toremifene or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1, wherein the (deaminohydroxy)toremifene is not a salt. 3. The method according to claim 1, wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered orally. 4. The method according to claim 2, wherein the (deaminohydroxy)toremifene is administered in a daily dose of 25 to 100 mg. 5. The method according to claim 2, wherein the (deaminohydroxy)toremifene is administered in a daily dose of 60 mg. 6. The method according to claim 5, wherein the (deaminohydroxy)toremifene is administered orally. 7. The method according to claim 1, wherein the woman is a postmenopausal woman. 8. The method according to claim 2, wherein the woman is a postmenopausal woman. 9. The method according to claim 6, wherein the woman is a postmenopausal woman. 10. The method according to claim 1, wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered in a daily dose of 30 to 90 mg. 11. The method according to claim 1, wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered in a daily dose of 60 mg. 12. The method according to claim 1, wherein the (deaminohydroxy)toremifene is administered orally in a daily dose of 60 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.